STOCK TITAN

Beta Bionics (NASDAQ: BBNX) investors approve directors and auditor

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Beta Bionics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of March 23, 2026, there were 44,561,695 shares outstanding, and a quorum of 36,061,048 shares was represented in person or by proxy.

Stockholders elected Class I directors Sean D. Carney and Christy Jones to serve until the 2029 Annual Meeting, with Carney receiving 30,659,060 votes for and Jones 25,865,542 votes for, alongside broker non-votes. Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares outstanding 44,561,695 shares Common stock outstanding as of March 23, 2026 record date
Quorum shares represented 36,061,048 shares Shares represented in person or by proxy at Annual Meeting
Votes for Sean D. Carney 30,659,060 votes Election of Class I director
Votes for Christy Jones 25,865,542 votes Election of Class I director
Broker non-votes (directors) 4,792,996 votes Broker non-votes reported for each director election
Votes for auditor ratification 36,011,432 votes Ratification of Ernst & Young LLP for FY ending Dec. 31, 2026
Votes against auditor ratification 41,527 votes Ratification of Ernst & Young LLP
Abstentions on auditor ratification 8,089 votes Ratification of Ernst & Young LLP
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."
quorum financial
"At the Annual Meeting, a quorum of 36,061,048 shares of the Company’s common stock were represented"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Class I directors financial
"elected two Class I directors, Sean D. Carney and Christy Jones, to hold office"
Class I directors are the subset of a company’s board whose terms expire at a specific annual meeting under a staggered election system that divides directors into multiple groups with different re-election years. For investors this matters because staggered classes slow how quickly shareholders can replace the board, affecting takeover risk, governance change and the pace of corporate decisions — like rotating only part of a team instead of swapping everyone at once.
independent registered public accounting firm financial
"ratified the appointment by the Audit Committee ... of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes financial
"Votes For | Votes Withheld | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Beta Bionics (BBNX) report from its 2026 Annual Meeting?

Beta Bionics reported final voting results from its 2026 Annual Meeting. Stockholders elected two Class I directors and ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026, with a quorum of 36,061,048 shares represented.

How many Beta Bionics (BBNX) shares were eligible to vote at the 2026 meeting?

44,561,695 shares of Beta Bionics common stock were eligible to vote. This figure reflects shares outstanding as of March 23, 2026, the record date for the Annual Meeting, establishing the base against which the 36,061,048-share quorum was measured.

Which directors were elected at the 2026 Beta Bionics (BBNX) Annual Meeting?

Stockholders elected Sean D. Carney and Christy Jones as Class I directors. They will serve until the 2029 Annual Meeting of Stockholders, or until earlier death, resignation, or removal, following majority support in the director election vote at the meeting.

What were the vote totals for Beta Bionics (BBNX) director elections?

Sean D. Carney received 30,659,060 votes for and 608,992 withheld, with 4,792,996 broker non-votes. Christy Jones received 25,865,542 votes for and 5,402,510 withheld, plus the same 4,792,996 broker non-votes reported in the director election results.

Which auditor did Beta Bionics (BBNX) stockholders ratify for 2026?

Stockholders ratified Ernst & Young LLP as Beta Bionics’ independent registered public accounting firm. For this proposal, 36,011,432 votes were cast for ratification, 41,527 against, and 8,089 abstentions for the fiscal year ending December 31, 2026.

Were there any other proposals at the 2026 Beta Bionics (BBNX) Annual Meeting?

No additional proposals were presented for stockholder approval. The meeting addressed only two items: election of the two Class I directors and ratification of Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year.
false 0001674632 0001674632 2026-05-21 2026-05-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2026

 

 Beta Bionics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 001-42491 47-5386878
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

 

11 Hughes

Irvine, California 92618

(Address of principal executive offices)

Registrant’s telephone number, including area code: (949) 427-7785

N/A

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
symbol(s)
  Name of each exchange
on which registered
Common Stock, $0.0001 par value per share   BBNX   Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 21, 2026, Beta Bionics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Company’s definitive proxy statement for the Annual Meeting was filed with the U.S. Securities and Exchange Commission on April 10, 2026 and describes in detail the two proposed voting matters (the “Proposals”) submitted to the Company’s stockholders at the Annual Meeting. The final results for the votes cast with respect to each Proposal are set forth below.

As of March 23, 2026, the record date for the Annual Meeting, there were 44,561,695 outstanding shares of the Company’s common stock. At the Annual Meeting, a quorum of 36,061,048 shares of the Company’s common stock were represented in person or by proxy.

Proposal 1. Election of Directors

The Company’s stockholders elected two Class I directors, Sean D. Carney and Christy Jones, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal, by the following vote:

 

Name of Director Votes For Votes Withheld Broker Non-Votes
Sean D. Carney 30,659,060 608,992 4,792,996
Christy Jones 25,865,542 5,402,510 4,792,996

 

Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, by the following vote:

 

Votes For Votes Against Abstentions
36,011,432 41,527 8,089

No other items were presented for stockholder approval at the Annual Meeting.

 

 

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Beta Bionics, Inc.
     
  By: /s/ Sean Saint
    Sean Saint
    President and Chief Executive Officer

Dated: May 22, 2026

Filing Exhibits & Attachments

3 documents